Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Glioblastoma 2Vaginal Neoplasms 1Lymphoma, Follicular 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

aldesleukin 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Brachytherapy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1talazoparib 1liposomal doxorubicin 1entinostat 1dostarlimab 1bintrafusp alfa protein, human 1belzutifan 1Therapeutic Touch 1Surveys and Questionnaires 1Specimen Handling 1Sonazoid 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Observation 1Nivolumab 1Methods 1Interviews as Topic 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Educational Status 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaginal Neoplasms × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 1 year × Clear all
NCT02466971 2026-05-29

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

National Cancer Institute (NCI)

Phase 3 Active not recruiting
450 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡